Jun 22, 2026
Investment Roundup: Q1 + Q2 2026
Six months of exciting updates from the UPMC Enterprises portfolio.
UPMC Enterprises upholds a dynamic portfolio of life sciences and digital health companies that we believe are paving the way for the future of health care. We are proud to celebrate new investments that support our mission and vision of UPMC, and support companies as they mature to acquisition.
These announcements were made possible by the amazing talent we have at UPMC Enterprises that powers our unique model. Explore the strategic investments and successful acquisitions our team has made during the first half of 2026.
Arrive Health
In March, Arrive Health merged with Dosespot and pVerify in 2026 to form Interra Health, which delivers the first patient-centric prescribing experience. By bringing together Arrive’s real-time cost and coverage insights with DoseSpot’s trusted ePrescribing and patient engagement tools, Interra Health will support nearly 800,000 prescribers and help improve medication access and adherence at the point of care.
Thank you to the following individuals for contributing to this transaction: Kathryn Heffernan, Tyler Crawford, and Craig Ball.
UPMC Enterprises remains a minority investor in Interra Health.
Koda Health
In April, UPMC Enterprises’ Series A investment in Koda Health, an AI-enhanced Advance Care Planning (ACP) platform, became public. While this investment was originally finalized in 2025, we are proud to announce this investment to support digitally guided, values-based advance care planning as a critical and underbuilt layer of serious illness infrastructure.
Thank you to the following individuals for contributing to this transaction: Dr. Andrew Watson, Kathryn Heffernan, Dan Tarpey, Ben Almassi, and Kritika Verma.
Ouro Medicines
In March, Ouro Medicines completed its acquisition by Gilead Sciences, marking the first exit of UPMC Enterprises’ life sciences portfolio. Like Gilead, the Enterprises team was attracted to Ouro’s unique approach to the development of treatments for autoimmune diseases — specifically its BCMAxCD3 T cell engager which has demonstrated B cell depletion in mid-stage clinical trials. Also known as an immune system reset, B cell depletion can potentially restore healthy immune function and potentially eliminate the need for chronic medication. We remain proud to have helped support the progress of this important area of drug development.
After investing in Ouro just over a year ago, UPMC has realized nearly 10x cash on cash return, with additional payments possible if Ouro hits future milestones. Thank you to the following individuals for contributing to this transaction: Rosheema Bala, Ketki Karanam, Jamie Bauersmith, Matthias Kleinz, Dave Gibson, and Margaret Steere.
Precede Biosciences
In January, UPMC Enterprises joined a strategic investment round for Precede Biosciences, a precision diagnostics and data company advancing the next generation of precision medicines. This Series B financing enables Precede to scale its platform, which supports the development and clinical use of today’s most intensively studied cancer therapies, and meet growing demand from developers of next-generation precision medicines.
Thank you to the following individuals for supporting this investment: Matthias Kleinz, Ketki Karanam, Julian Hassinger, John Lowman, and Dr. Adrian Lee.
RAAPID, Inc.
In March, UPMC Enterprises successfully completed a strategic investment in RAAPID, Inc., an AI-native health care risk adjustment and revenue accuracy platform. RAAPID drives value for payers and risk-bearing providers by aligning risk adjustment coding with medical chart documentation. We are eager to support RAAPID in their mission to reshape compliant health care risk adjustment and reimbursement accuracy.
Thank you to the following individuals for supporting this investment: Matt Grant, Nick Shapiro, Maryam Jalal, Craig Ball, Jeff Taylor, Lis Giardino, and Matt Junker.
RxAnte
In January, RxAnte closed a major private equity investment that sets up the longtime portfolio company for continued growth and success. Primus Capital, a pharmacy private equity firm with a successful 40-year track record, acquired a majority stake in RxAnte. The deal also represents a significant return on investment for UPMC, which has been a partner with RxAnte, a provider of analytics, software, and services for pharmacy care management, since 2016.
Our Digital Solutions team not only provided diligence and effort in shepherding this deal across the finish line, but also have acted as a strong partner for RxAnte over the years. Thank you to the following individuals for contributing to this transaction: Margaret Steere, Dave Gibson, Nick Shapiro, and Kathryn Heffernan.
UPMC continues to own a minority stake in RxAnte and remains a key partner; Brent Burns continues to serve on the company’s board.
